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ABSTRACT
Oral conditions such as gingivitis and chronic periodontitis are found worldwide and are among the
most prevalent microbial diseases of mankind. The cause of these common inﬂammatory conditions is
the complex microbiota found as dental plaque, a complex microbial bioﬁlm. Despite 3000 years of
history demonstrating the inﬂuence of oral status on general health, it is only in recent decades that the
association between periodontal diseases and systemic conditions such as coronary heart disease and
stroke, and a higher risk of preterm low birth-weight babies, has been realised. Similarly, recognition of
the threats posed by periodontal diseases to individuals with chronic diseases such as diabetes,
respiratory diseases and osteoporosis is relatively recent. Despite these epidemiological associations, the
mechanisms for the various relationships remain unknown. Nevertheless, a number of hypotheses have
been postulated, including common susceptibility, systemic inﬂammation with increased circulating
cytokines and mediators, direct infection and cross-reactivity or molecular mimicry between bacterial
antigens and self-antigens. With respect to the latter, cross-reactive antibodies and T-cells between self
heat-shock proteins (HSPs) and Porphyromonas gingivalis GroEL have been demonstrated in the
peripheral blood of patients with atherosclerosis as well as in the atherosclerotic plaques themselves. In
addition, P. gingivalis infection has been shown to enhance the development and progression of
atherosclerosis in apoE-deﬁcient mice. From these data, it is clear that oral infection may represent a
signiﬁcant risk-factor for systemic diseases, and hence the control of oral disease is essential in the
prevention and management of these systemic conditions.
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INTRODUCTION
Cardiovascular disease (CVD), including
atherosclerosis, myocardial infarction and stroke,
is the leading cause of death in many societies
(http://www.who.int/cardiovascular_diseases/en/).
CVD accounts for an estimated 40% of all deaths
worldwide, with atherosclerosis being the under-
lying aetiology in the vast majority of cases.
In many countries, the death rate is often
highest among indigenous populations and those
from low socio-economic backgrounds. In New
Zealand, for example, death rates are highest
among Maoris, followed by Paciﬁc people, and
lowest among those of neither Maori nor Paciﬁc
origin. Fifty-six per cent of Maori males and
34% of Maori females who died from coronary
heart disease were under the age of 65 years,
compared with 16% of males and 5% of females
among those of neither Maori nor Paciﬁc
origin [1].
Up to 50% of individuals with CVD may not
have any of the traditional risk-factors such as
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smoking, obesity, hypercholesterolaemia, high
blood pressure or diabetes. Therefore, it is impor-
tant to understand all possible risk-factors if
morbidity and mortality due to this disease are
to be reduced. Risk-factors are the key to preven-
tion, and even a modest change in risk can lead to
a signiﬁcant change in disease burden. The
importance of the role of infection and inﬂamma-
tion in the initiation and progression of athero-
sclerosis is now widely accepted [2–9].
Chronic inﬂammatory periodontal diseases are
found worldwide and are among the
most prevalent chronic infections in humans.
Advanced forms of the disease can be found in
10–15% of the population and constitute a con-
siderable inﬂammatory burden (Fig. 1). Individ-
uals with severe chronic periodontitis have been
reported to have a signiﬁcantly increased risk of
developing CVD, including atherosclerosis, myo-
cardial infarction and stroke, after adjusting for
many of the traditional risk factors [10–16].
Jansson et al. [16] found that after adjustment for
age, gender, smoking and CVD at baseline, oral
health was signiﬁcantly correlated with fatal
coronary events. In fact, these authors made the
extraordinary statement that oral health was a
risk indicator of death due to CVD.
There have now been over 50 studies investi-
gating the relationship between periodontal dis-
ease and CVD, with the majority showing a
signiﬁcant, albeit modest, positive association
even after adjusting for confounders. Two recent
meta-analyses [17,18] have also concluded that
periodontal disease and CVD are signiﬁcantly
related. Despite this, the association between
periodontal disease and CVD has been ques-
tioned [19] to such a degree that current opinion
regarding the relationship is still divided. In this
context, longitudinal intervention and pathogenic
mechanism studies are urgently required. Several
hypotheses, including common susceptibil-
ity, direct bacterial damage to the endothelium,
systemic inﬂammation and, ﬁnally, cross-reactiv-
ity or molecular mimicry between bacterial anti-
gens and self-antigens have, nevertheless, been
proposed to explain the relationship [20].
COMMON SUSCEPTIBILITY MODEL
Common susceptibility involves a genetically
determined phenotype, which leads to a greater
risk of both artherosclerosis and infection. In this
hypothesis, in the presence of periodontal patho-
gens, a susceptible person develops periodontal
disease. This same person would also be suscep-
tible to atherosclerosis, but, in this model the
periodontal disease does not cause the athero-
sclerosis.
SYSTEMIC INFLAMMATION MODEL
A second hypothesis is that of systemic inﬂam-
mation and increased circulating cytokines and
inﬂammatory mediators. In this hypothesis,
inﬂammation leads to an increase in the levels
of circulating cytokines, which in turn damage the
vascular endothelium and ultimately result in
atherosclerosis. The circulating cytokines of cur-
rent interest include: C-reactive protein (CRP),
interleukin-1, interleukin-6 (IL-6), tumour necro-
sis factor-a, and prostaglandin E2. The highest
relative risk-factor for myocardial infarction was
found to be the levels of CRP together with the
ratio of total cholesterol to high-density lipid [21].
A number of studies have shown that chronic
periodontitis is associated with increased levels of
CRP [22–24]. In our recent study of over 400
patients with deﬁned CVD, the highest levels of
CRP were seen in those with the most advanced
periodontal disease (Fig. 2).
Measures of endothelial dysfunction
Flow-mediated dilatation.
Flow-mediated dilatation measures the capacity
of the arteries to dilate in response to altered ﬂow.
It has been shown that ﬂow-mediated dilation is
Fig. 1. Patient with chronic inﬂammatory periodontal
disease, illustrating the considerable inﬂammatory burden.
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decreased in severe periodontal disease and that
this is associated with high levels of CRP [22,23].
Recently, Tonetti et al. showed that 24 h after
intensive periodontal therapy, brachial artery
elasticity, as measured by ﬂow-mediated dilata-
tion, was signiﬁcantly lower than that in the
control treatment group [24]. This was associated
with increased levels of CRP and IL-6. By 60 and
180 days, however, ﬂow-mediated dilatation was
greater in the intensive therapy group and the
plasma levels of E-selectin were lower. This
degree of improvement in the intensive therapy
group was associated with a signiﬁcant improve-
ment in periodontal health.
Pulse-wave velocity.
Recently, Amanuma et al. (85th annual IADR
meeting, March 2007, Abstract 2322) used pulse-
wave velocity (PWV) to determine the effect of
periodontal treatment on arterial elasticity in a
Japanese population. PWV is a reﬂection of
arterial stiffness, and an elevated PWV is associ-
ated with atherosclerosis, increased cardiovascu-
lar events and increased mortality. In addition to
PWV, these authors also measured serum levels
of high-sensitivity CRP, IL-6 and tumour necrosis
factor-a in 39 patients with periodontitis before
and after periodontal treatment, and in 22 sys-
temically and periodontally healthy control sub-
jects. They found that the level of PWV in the
patient group tended to be higher than in the
controls, and that the level decreased after peri-
odontal treatment. They also showed that the
levels of high-sensitivity CRP and IL-6, but
not tumour necrosis factor-a, decreased after
periodontal treatment. These results suggest that
chronic inﬂammatory periodontal disease may
affect endothelial cell dysfunction either directly
or indirectly via stimulation of CRP synthesis in
the liver.
INFECTION MODEL
A third hypothesis is direct infection of the blood
vessels by bacteria. In this hypothesis, the bacte-
rial pathogens get into the bloodstream, and
subsequently invade the endothelium, leading
to endothelial dysfunction, inﬂammation and
atherosclerosis.
Several studies have shown bacteria in the
atherosclerotic plaques. In a study by Ford et al.
[25], real-time PCR was used to show Porphyro-
monas gingivalis in 100% of atherosclerotic
plaques. Fusobacterium nucleatum was found in
approximately 80%, Tannerella forsythia in just
under 50%, and Chlamydia pneumoniae in just
under 30%. Helicobacter pylori and Haemophilus
inﬂuenzae were both found in approximately 4%
of the arteries. These results clearly show that
oral organisms can and do invade blood vessel
walls, but it is unclear whether they cause the
atherosclerosis or simply invade an already
damaged artery.
CROSS-REACTIVITY ⁄ MOLECULAR
MIMICRY MODEL
In this hypothesis [26], the progression of athero-
sclerosis can be explained in terms of the immune
response to bacterial heat-shock proteins (HSPs).
All cells express HSPs upon exposure to various
forms of stress [27,28], and bacterial HSPs are
major antigenic determinants during infection
[29]. The immune system may not be able to
differentiate between self-HSP and bacterial HSP;
thus, during infection, cross-reactive T-cells with
speciﬁcity for self-HSP may be activated [30], and
antibodies produced by the host directed at
bacterial HSP could result in an autoimmune
response to similar antigenic structures in the host
[27,29].
Concerning atherosclerosis, factors such as
bacterial lipopolysaccharide, cytokines and
mechanical stress may induce the expression of
host protective HSP (hHSP60) on endothelial
cells. Owing to the homologous nature of HSPs
among species [31], cross-reactivity of antibodies
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Fig. 2. Levels of C-reactive protein in subjects with diag-
nosed cardiovascular disease. The highest levels are seen
in those with advanced periodontal disease (AP), as
compared with those with moderate disease (MP) and
those with healthy gingivae or gingivitis (H ⁄G).
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to bacterial HSP (termed GroEL) with hHSP60 on
endothelial cells may subsequently result in
endothelial dysfunction and induce the develop-
ment of atherosclerosis [26]. The presence of risk-
factors such as high blood cholesterol would
enhance the expression of hHSP60 and adhesion
molecules by endothelial cells, such that subse-
quent immune cross-reactivity could result in
progression from early fatty streak lesions to
severe and irreversible atherosclerosis. A correla-
tion between high anti-HSP60 ⁄ 65 antibody titres
and high morbidity and mortality due to athero-
sclerosis has been demonstrated [32], and these
antibodies were shown to be cross-reactive with
those of other bacteria and were able to lyse
stressed, but not unstressed, endothelial cells [33].
The demonstration of elevated hHSP60 levels in
patients with borderline hypertension, and an
association between early atherosclerosis and
HSP60 levels [34], offer further support for this
hypothesis.
GroEL proteins of the HSP60 family have been
reported to be major antigens in several patho-
genic bacteria [35]. An Escherichia coli GroEL
homologue has been identiﬁed in the periodon-
topathic bacteria P. gingivalis, F. nucleatum and
Aggregatibacter actinomycetemcomitans [36,37],
which was immunogenic and recognised by
serum antibodies in patients with periodontal
disease [37]. GroEL antigens share a high degree
of homology with hHSP60 proteins, and antibody
to hHSP60 cross-reacts with periodontopathic
bacterial GroEL [38]. Patients with periodontal
disease were shown to have a higher positive
response to P. gingivalis GroEL antigens than did
healthy controls. Cross-reactivity between P. gin-
givalis GroEL antibodies and hHSP60, and be-
tween antibodies to hHSP60 and P. gingivalis
GroEL, has been demonstrated [39].
Studies in our laboratory [25] have conﬁrmed
the expression of hHSP60 on endothelial cells and
also on ﬁbroblast ⁄ smooth muscle cells in athero-
sclerotic lesions in humans. We also examined
anti-hHSP60 and anti-P. gingivalis GroEL anti-
body levels in serum samples from 130 patients
with CVD. Higher levels were detected in patients
with moderate ⁄ advanced periodontitis. Levels of
anti-GroEL and anti-P. gingivalis antibodies in
plasma samples from atherosclerosis patients
were reduced following absorption with hHSP60
in 19 ⁄ 22 patients, thus demonstrating cross-reac-
tivity.
In addition, we have examined anti-hHSP60
and anti-P. gingivalis GroEL antibody levels in
serum from patients with diagnosed CVD, as
well as from patients with both low and high
cardiovascular risk. Levels of anti-hHSP60 anti-
bodies were signiﬁcantly greater in patients with
high cardiovascular risk than in patients with
low risk and diagnosed CVD. Levels of
antibodies to P. gingivalis GroEL were also sig-
niﬁcantly greater in patients with high cardio-
vascular risk than in low-risk patients. There
was no signiﬁcant difference in antibody levels
between those with diagnosed CVD and those
with low risk. However, patients with diagnosed
CVD were receiving therapy, which may explain
the reduction to an antibody level comparable to
that of low-risk patients. We also examined the
cross-reactivity of anti-hHSP60 antibodies with
P. gingivalis antigens. After absorption with
P. gingivalis, there was a signiﬁcant reduction
in the level of anti-hHSP60 antibodies in
patients with diagnosed CVD, as compared with
low-risk and high-risk patients. That is, patients
with diagnosed CVD had a greater amount of
cross-reactivity between anti-hHSP60 antibodies
and P. gingivalis antigens. While cardiovascular
therapy may have lowered the levels of anti-
hHSP60 and anti-GroEL antibodies, the amount
of cross-reactivity was unchanged (unpublished
data).
We have established GroEL-, hHSP60- and
P. gingivalis-speciﬁc T-cell lines from peripheral
blood and from human atherosclerotic plaques
[40]. Of particular note was the cross-reactivity of
a number of GroEL-speciﬁc T-cell lines with
hHSP60 and of hHSP60-speciﬁc lines with GroEL,
again suggesting molecular mimicry of GroEL
and hHSP60. These results demonstrated the
presence of T-cells speciﬁc for GroEL in the
peripheral blood, as well as in atherosclerotic
lesions, and their cross-reactivity with hHSP60
[40]. The cytokine, chemokine and V Beta proﬁles
of these cells are similar to those demonstrated
previously for P. gingivalis – speciﬁc T cell lines
from patients with periodontal disease [41–43].
Furthermore, Yamazaki et al. [44] have demon-
strated that HSP60-stimulated peripheral blood
mononuclear cells and P. gingivalis GroEL-stimu-
lated peripheral blood mononuclear cells had
identical nucleotide sequences in the CDR3 of the
T-cell receptor (TCR) b-chain and that T-cells with
the same nucleotide sequences were present in
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the gingival tissues as well as in atherosclerotic
aneurysmal tissues.
We now have preliminary data showing that
peripheral blood T-cells from young adults (aged
<35 years) without periodontal disease or clini-
cally evident atherosclerosis do not respond to
either HSP60 or P. gingivalis outer-membrane
preparation containing GroEL (as conﬁrmed by
western blot), thus adding further weight to the
proposed hypothesis that molecular mimicry may
be a mechanism involved in atherosclerosis, at
least in some patients [45, 46].
The development of murine models of athero-
sclerosis has provided a valuable tool for the
study of factors involved in atherogenesis. Im-
munisation of C57BL ⁄ 6 mice (on a cholesterol-
rich diet) with recombinant HSP has been shown
to signiﬁcantly increase the development of ath-
erosclerosis [47], suggesting that hHSP60 may
play a major role in inducing atherosclerosis.
Using the apoE-deﬁcient mouse model, studies
have demonstrated that repeated inoculation with
P. gingivalis results in atherosclerotic lesions that
are more advanced and develop more rapidly
than those in control mice [48,49]. We have also
shown that, in this model, weekly intraperitoneal
injections of either P. gingivalis or C. pneumoniae
resulted in marked atherosclerotic lesions in the
proximal aorta, while control mice showed no
lesions (Fig. 3). Furthermore, while lesions devel-
oped later with P. gingivalis, as compared with
C. pneumoniae, an increase in the pathogen burden
of P. gingivalis, but not of C. pneumoniae,
enhanced atherosclerosis [50]. An increased path-
ogen load also resulted in increased titres of
speciﬁc antibody in the case of P. gingivalis but
not in the case of C. pneumoniae, suggesting that
the peak atherosclerotic response to P. gingivalis
coincided with the peak antibody response. There
was a signiﬁcant correlation between anti-GroEL
antibody levels and lesion size (p <0.05)
(r ¼ 0.77), which further suggests that immuno-
logical cross-reactivity could be involved.
CONCLUSION
Taken together, these results show that HSPs are
expressed in atherosclerotic plaques, and that
cross-reactive T-cells exist in periodontal disease
tissue, in peripheral blood and in atherosclerosis
lesions, thus strongly supporting the hypothesis
that cross-reactivity of the immune response to
bacterial HSPs with arterial endothelial cells
expressing hHSP60 may be a mechanism
involved in the disease process of atherosclerosis,
at least in some patients.
Ang et al. [51] have put forward four criteria for
diseases mediated by molecular mimicry.
1. Establishment of an epidemiological associa-
tion between the infectious agent and the
immune-mediated disease.
2. Identiﬁcation of T-cells or antibodies directed
against host target antigens.
3. Identiﬁcation of the microbial mimic of the
target antigen.
4. Reproduction of the disease in an animal
model.
As indicated above, there is clear evidence of an
epidemiological association between periodontal
disease and CVD. The results of our studies in
Brisbane and Niigata provide data that fulﬁl
criteria 2 and 3. We have identiﬁed the microbial
target; we have shown that there are antibodies
and T-cells that react with this target; we have
identiﬁed the human antigens with which these
cells and antibodies cross-react; we have shown
that these cells are in the arteries as well as in the
gingival tissues; and we have shown that these
cells are in the peripheral blood of patients with
atherosclerosis. Furthermore, the studies of
Li et al. [48] and Lalla et al. [49], together with
our own studies [50], have shown that infection
with P. gingivalis also accelerates the progression
of atherosclerosis in apoE-deﬁcient mice. Taken
Fig. 3. After 11 weekly injections, immunised mice dem-
onstrate marked atherosclerotic lesions in the proximal
aorta, while control mice show no lesions. The dark
staining area in the wall of the aorta is a lipid-ﬁlled
atherosclerotic lesion from an immunised mouse.
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together, these results provide data that fulﬁl all
four criteria for diseases mediated by molecular
mimicry and, therefore, support for the concept
that cross-reactivity between GroEL and HSP60
represents, at least in part, the link between
infection, including periodontal disease, and
CVD.
It is clear, therefore, that infection can contrib-
ute to atherosclerosis via molecular mimicry. This
infection could be respiratory, e.g., C. pneumoniae,
gastrointestinal, e.g., H. pylori, or oral, e.g., P. gin-
givalis. These all contribute to the total burden of
infection; in some individuals, oral infection may
make a signiﬁcant contribution to the total burden
of infection, while in others it may be only a
minor contributor. Nevertheless, it is the respon-
sibility of all health professionals to ensure that all
oral infection is kept to a minimum. All such
infections lead to inﬂammation in the respective
tissue and contribute to the total burden of
inﬂammation, which in turn can contribute to
atherosclerosis. Obesity, diabetes and other auto-
immune diseases such as rheumatoid arthritis can
also contribute to the total burden of inﬂamma-
tion and hence to atherosclerosis. Atherosclerosis
itself is an inﬂammatory condition that contrib-
utes to the total burden of inﬂammation. All these
interactions are shown in Fig. 4, which begins to
explain the observed associations between peri-
odontal disease, atherosclerosis, diabetes, rheu-
matoid arthritis, smoking, mental stress, etc.
Overall, it is an extremely complex interaction,
and no one mechanism is likely to provide the
complete explanation.
Nevertheless, the importance of preventing and
treating infections, especially chronic infections
such as periodontitis, would become paramount
in advising and treating patients with coronary
heart disease. Effective health policy needs to
focus on risk-factors, as even modest changes in
risk can have signiﬁcant changes in disease
burden. If periodontal disease proves to be a
risk-factor for CVD, this will clearly establish the
need for adult oral health programmes, together
with diet, exercise and smoking control, in the
treatment and prevention of CVD. In terms of the
‘health payback model’, understanding the rela-
tionship between oral infection and systemic
diseases has the potential to change health policy
with ensuing economic beneﬁts.
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